Seegene and Eidia join forces to bring multiplex molecular diagnostic tests to Japan, 9/13

Seegene has entered into a collaborative agreement with Eidia, the in vitro diagnostics subsidiary arm of Eisai Co., headquartered in Japan. Through this agreement, Eidia gains access to Seegene’s portfolio of Toce technology-based multiplex molecular diagnostic tests for the Japanese diagnostic test market.

Under terms of the deal, Seegene will supply a range of Toce technology-based multiplex molecular diagnostic tests, and Eidia will exclusively market and distribute them in Japan. In addition, Eidia will be responsible for obtaining regulatory clearance from the Japanese Pharmaceutical and Medical Device Agency.

Seegene, 301-762-9066